Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | BCR | P11274 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
| ▸ | ROS1 | P08922 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.35 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.35 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16719384 | 0.86 | TGFBR1 (0.36) | ABL1ABCB1BCRTGFBR1ROS1 | |
| SCHEMBL16720648 | 0.79 | IDO1 (0.46) | TGFBR1CYP1A1CYP1B1KDM4EMEN1 | |
| SCHEMBL28895988 | 0.73 | TGFBR1 (0.45) | TGFBR1MAPKAPK2KDM4EALDH1A1MAPT | |
| SCHEMBL18015361 | 0.68 | NPC1 (0.35) | ABL1BCRTGFBR1MEN1ALDH1A1 | |
| SCHEMBL21331583 | 0.68 | ABL1 (0.55) | ABL1ABCB1BCRTP53MAPT | |
| SCHEMBL29616810 | 0.68 | ABL1 (0.55) | ABL1ABCB1BCRTP53MAPT | |
| SCHEMBL16719529 | 0.67 | IDO1 (0.39) | CYP1A1CYP1B1KDM4EMEN1ALDH1A1 | |
| SCHEMBL16719832 | 0.67 | SMN1; SMN2 (0.44) | TGFBR1ROS1MAPKAPK2CYP1A2CYP2D6 | |
| SCHEMBL704826 | 0.65 | RAB9A (0.46) | TGFBR1ALDH1A1MAPTSMN1; SMN2CCR1 | |
| SCHEMBL30607044 | 0.65 | ESR2 (0.38) | ABL1ABCB1BCRCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2025-03-25 | — | — | US | disclosed |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | WISTAR INST (US) | 2022-12-15 | — | — | US | disclosed |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | WISTAR INST (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-9856214-B2 | EBNA1 inhibitors and their method of use | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-06 | — | — | US | disclosed |
| EP-3068758-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | The Wistar Institute Of Anatomy And Biology (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015073864-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258314-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | ABL1 539/4885ABCB1 745/4885BCR 426/4885 |
| US-11242317-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | ABL1 539/4885ABCB1 745/4885BCR 426/4885 |
| US-20160289185-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | MCM5, EBNA1BP2, MLLT1 | ABL1 584/4885ABCB1 1206/4885BCR 574/4885 |
| US-20200181078-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | ABL1 539/4885ABCB1 745/4885BCR 426/4885 |
| US-10421718-B2 | EBNA1 inhibitors and their method of use | EBNA1BP2, MLLT1, PML | ABL1 539/4885ABCB1 745/4885BCR 426/4885 |
| US-20180086699-A1 | EBNA1 INHIBITORS AND THEIR METHOD OF USE | EBNA1BP2, MLLT1, PML | ABL1 539/4885ABCB1 745/4885BCR 426/4885 |
| US-20220396551-A1 | EBNA1 Inhibitors and Their Method of Use | EBNA1BP2, MLLT1, PML | ABL1 539/4885ABCB1 745/4885BCR 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.